{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:00:33Z","timestamp":1773010833027,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T00:00:00Z","timestamp":1383523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"Background and purpose<\/jats:title>High dose intravenous immunoglobulin (IVIG<\/jats:styled-content>) is an established treatment for various neuromuscular disorders. Recently, cases of hemolytic anemia following IVIG<\/jats:styled-content> have been observed. The objective of this study was to determine the extent of anemia and hemolysis after IVIG<\/jats:styled-content> and its relationship to the AB<\/jats:styled-content>0 blood type system.<\/jats:p><\/jats:sec>Methods<\/jats:title>In a prospective study 34 de novo<\/jats:italic> treated patients were given 2.0\u00a0g\/kg bodyweight of Privigen and 50 patients received either Privigen [n<\/jats:italic>\u00a0=\u00a028; 1.53\u00a0\u00b1\u00a00.4\u00a0g\/kg (mean \u00b1 SD<\/jats:styled-content>)] or Kiovig (n<\/jats:italic>\u00a0=\u00a022; 1.7\u00a0\u00b1\u00a00.4\u00a0g\/kg) as maintenance therapy. The de novo<\/jats:italic> patients all had a post\u2010polio syndrome, whereas the remaining patients received maintenance therapy for the neuromuscular disorders chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy. Blood sampling was performed before and 2\u00a0weeks after infusion of IVIG<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>Following IVIG<\/jats:styled-content> treatment blood hemoglobin declined from 8.6\u00a0\u00b1\u00a00.9 to 8.0\u00a0\u00b1\u00a01.2\u00a0mM, P<\/jats:italic>\u00a0<\u00a00.001. Reticulocyte counts and levels of bilirubin and lactate dehydrogenase were increased and haptoglobin levels decreased. The decline of hemoglobin was 0.9\u00a0\u00b1\u00a01.2\u00a0mM<\/jats:sc> after de novo<\/jats:italic> therapy versus 0.4\u00a0\u00b1\u00a00.8\u00a0mM after maintenance therapy with Privigen (P<\/jats:italic>\u00a0=\u00a00.05) and 0.2\u00a0\u00b1\u00a00.3\u00a0mM after maintenance therapy with Kiovig (P<\/jats:italic>\u00a0=\u00a00.47). In de novo<\/jats:italic> patients compared with patients on maintenance therapy reticulocyte count and lactate dehydrogenase level increased whereas haptoglobin level decreased. Anemia correlated with the AB<\/jats:styled-content>0 blood type system with a significant difference between type 0 (n<\/jats:italic>\u00a0=\u00a017; +0.3\u00a0\u00b1\u00a00.4\u00a0mM) and type A<\/jats:styled-content>, B<\/jats:styled-content> and AB<\/jats:styled-content> (n<\/jats:italic>\u00a0=\u00a048; \u22121.0\u00a0\u00b1\u00a01.0\u00a0mM), anemia being most pronounced in type AB<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Moderate hemolytic anemia is a concomitant complication of high dose IVIG<\/jats:styled-content> in subjects with blood types A<\/jats:styled-content>, B<\/jats:styled-content> and AB<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.12287","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T10:40:52Z","timestamp":1383561652000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders"],"prefix":"10.1111","volume":"21","author":[{"given":"L. H.","family":"Markvardsen","sequence":"first","affiliation":[{"name":"Department of Neurology Aarhus University Hospital Aarhus C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Department of Neurology Rigshospitalet Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Harbo","sequence":"additional","affiliation":[{"name":"Department of Neurology Aarhus University Hospital Aarhus C Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Neurology Aarhus University Hospital Aarhus C Denmark"},{"name":"Department of Neurology Rigshospitalet Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2212Barr\u00e9 syndrome","volume":"7","author":"Doorn PA","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_3_1","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos P","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00290.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-0502(03)00012-0"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.9.836-b"},{"key":"e_1_2_6_8_1","first-page":"1963","article-title":"Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin","volume":"173","author":"Juel J","year":"2011","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12182"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1142::AID-MUS8>3.0.CO;2-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04540709"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1205644"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01721.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21263"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1987.27187121468.x"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.12287","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.12287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:20:44Z","timestamp":1696299644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.12287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,4]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/ene.12287"],"URL":"https:\/\/doi.org\/10.1111\/ene.12287","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,4]]},"assertion":[{"value":"2013-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}